Hematological disorders and leukemia in children with Down syndrome
- 24 November 2011
- journal article
- review article
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 171 (9) , 1301-1307
Abstract
Constitutional trisomy 21 inherent to Down syndrome (DS) is associated with several hematological disorders occurring at different ages. Neonates with DS may present with transient asymptomatic blood count abnormalities such as neutrophilia, thrombocytopenia and polycythemia. Within 1–2 months of life, 3–10% of DS infants develop transient myeloproliferative disease. Despite a spontaneous regression in most of the cases, TMD can be fatal or lead to the subsequent development of myeloid leukemia in 20% of DS children (DS ML). DS ML has clinical and biological features that define a unique entity with a high sensitivity to chemotherapy and a favorable outcome. Children with DS also have an increased risk of developing acute lymphoblastic leukemia (ALL) characterized by a more heterogeneous pattern of genetic findings and by a higher rate of treatment-related toxicities. These features highlight the role of trisomy 21 in leukemogenesis and confirm the need of specific and adapted therapeutic approach for DS children with leukemia.Keywords
This publication has 37 references indexed in Scilit:
- Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trialBlood, 2011
- CRLF2 and JAK2 in B-Progenitor Acute Lymphoblastic Leukemia: A Novel Association in OncogenesisCancer Research, 2010
- Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology GroupBlood, 2010
- Clinical practiceEuropean Journal of Pediatrics, 2010
- Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemiaNature Genetics, 2009
- Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndromeBlood, 2009
- Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndromeBlood, 2009
- Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemiaBritish Journal of Haematology, 2009
- Treatment and prognostic impact of transient leukemia in neonates with Down syndromeBlood, 2008
- Intrinsic Abnormalities of Lymphocyte Counts in Children with Down SyndromeThe Journal of Pediatrics, 2005